COMMUNIQUÉS West-GlobeNewswire

Cidara Therapeutics Receives U.S. FDA Breakthrough Therapy Designation for CD388 in Seasonal Influenza Prevention
09/10/2025
Breakthrough Therapy designation comes in addition to previously awarded Fast Track designation SAN DIEGO, Oct. 09, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its [...]
ABLi Therapeutics Reports Final Results from the Phase 2 ‘201 Trial’ Evaluating Risvodetinib for the Treatment of Parkinson’s Disease
09/10/2025
Risvodetinib demonstrated to be safe and well-tolerated with preliminary clinical benefits Risvodetinib demonstrated to be the first treatment to reduce alpha-synuclein pathology, widely recognized as the underlying [...]
Milestone® Pharmaceuticals to Present Data on Etripamil at the American Heart Association Scientific Sessions 2025
09/10/2025
MONTREAL and CHARLOTTE, N.C., Oct. 09, 2025 (GLOBE NEWSWIRE) -- Milestone ® Pharmaceuticals Inc. (Nasdaq: MIST) a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular [...]
vTv Therapeutics Announces New Appointments to its Scientific Advisory Board
09/10/2025
Board to offer guidance on clinical development of cadisegliatin for type 1 diabetes as company has initiated Phase 3 trials HIGH POINT, N.C., Oct. 09, 2025 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a [...]
Ariceum Therapeutics Data at the 2025 European Association of Nuclear Medicine Annual Congress Further Supports the Advancement of 225Ac-SSO110 for Extensive Stage Small Cell Lung Cancer and Merkel Cell Carcinoma
09/10/2025
Oral presentation by Dr Zan highlighted novel Phase 1/2 SANTANA-225 study design of 225Ac-SSO110 in patients with ES-SCLC or MCC 225Ac-SSO110 achieves superior pharmacokinetics with minimal re-distribution of Actinium- [...]
Tensive publishes positive long-term clinical follow-up data in Breast Cancer on REGENERA™ / SOFTAG™ breast implant
09/10/2025
24-month Phase I follow-up data show positive outcomes are maintained High levels of investigator and patient satisfaction, excellent safety profile Ongoing registrational trial will yield top-line results before the [...]
Italfarmaco Appoints Francesco Di Marco as Chief Executive Officer
09/10/2025
MILAN, Italy, October 09, 2025 – Italfarmaco S.p.A. today announced that Dr. Francesco Di Marco has been appointed as Chief Executive Officer (CEO), effective January 1, 2026. Dr. Di Marco brings over 25 years of [...]
Fagron reports solid third quarter performance with 6.4% revenue growth and confirms full year outlook
09/10/2025
Regulated information - inside information Nazareth (Belgium)/Rotterdam (The Netherlands), 9 October 2025 – 7:00 AM CET Fagron reports solid third quarter performance with 6.4% revenue growth and confirms full year [...]
Santhera Secures Agreement with Biomedica for the Distribution of AGAMREE® (Vamorolone) in Russia
09/10/2025
Pratteln, Switzerland, October 9, 2025 – Santhera Pharmaceuticals (SIX: SANN) announces the signing of an exclusive agreement with Biomedica for the distribution of AGAMREE® (vamorolone) in Russia, for the treatment of [...]
Zelluna Receives Positive MHRA Feedback and Strengthens UK Clinical Strategy for ZI-MA4-1 Paving the Way for First-in-Human Trials in the UK
09/10/2025
On track to file CTA by year end 2025, with plan to dose first patients and deliver initial data in 2026 Planned UK trial to be led by Prof. Fiona Thistlethwaite at The Christie NHS Foundation Trust, a European hub for [...]
Apogee Therapeutics, Inc. Announces Pricing of $300 Million Underwritten Public Offering
09/10/2025
SAN FRANCISCO and BOSTON, Oct. 08, 2025 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage biotechnology company advancing optimized, novel biologics with potential for best-in-class profiles [...]
PetMed Express, Inc. Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
08/10/2025
DELRAY BEACH, Fla., Oct. 08, 2025 (GLOBE NEWSWIRE) -- PetMed Express, Inc. (the “Company”) dba PetMeds and parent company of PetCareRx (NASDAQ: PETS), today announced that on September 9, 2025, the Compensation and [...]
Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities
08/10/2025
ZUG, Switzerland, Oct. 08, 2025 (GLOBE NEWSWIRE) -- The attached notification relates to the vesting and settlement of RSUs previously granted to a director of the Company. Attachment Notification of managers' [...]
BrightSpring Health Services, Inc. to Announce Third Quarter 2025 Financial Results on October 31, 2025
08/10/2025
LOUISVILLE, Ky., Oct. 08, 2025 (GLOBE NEWSWIRE) -- BrightSpring Health Services, Inc. (“BrightSpring” or the “Company”) (NASDAQ: BTSG) announced today that it plans to release its third quarter 2025 financial results on [...]
Dentsply Sirona to Host Third Quarter Conference Call on November 6th
08/10/2025
CHARLOTTE, N.C., Oct. 08, 2025 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. (“Dentsply Sirona” or the "Company") (Nasdaq: XRAY) today announced that the Company will host an investor conference call and live webcast on [...]
AMN Healthcare to Hold Third Quarter 2025 Earnings Conference Call on Thursday, November 6, 2025
08/10/2025
DALLAS, Oct. 08, 2025 (GLOBE NEWSWIRE) -- AMN Healthcare Services, Inc. (NYSE: AMN), has scheduled a conference call to discuss its third quarter 2025 financial results and fourth quarter 2025 outlook on Thursday, [...]
Greenspace Herbs Unveils Physics-Driven Quantum Ayurveda at SupplySide Global
08/10/2025
BANGALORE, India, Oct. 08, 2025 (GLOBE NEWSWIRE) -- Greenspace Herbs , a botanical science company merging ancient Ayurveda with quantum physics, will debut its Quantum Ayurveda™ technology during a live demonstration [...]
Libtayo® (cemiplimab-rwlc) Approved in the U.S. as First and Only Immunotherapy for Adjuvant Treatment of Cutaneous Squamous Cell Carcinoma (CSCC) with a High Risk of Recurrence After Surgery and Radiation
08/10/2025
Approval based on pivotal Phase 3 C-POST trial showing Libtayo significantly reduced the risk of disease recurrence or death by 68% compared to placebo (hazard ratio: 0.32; 95% confidence interval: 0.20-0.51; p<0. [...]
Apogee Therapeutics, Inc. Announces Proposed Underwritten Public Offering
08/10/2025
SAN FRANCISCO and BOSTON, Oct. 08, 2025 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage biotechnology company advancing optimized, novel biologics with potential for best-in-class profiles [...]

Pages